DBV Technologies (NASDAQ:DBVT) Trading Up 10% – Still a Buy?

DBV Technologies S.A. (NASDAQ:DBVT) traded up 10% during trading on Monday . The company traded as high as $23.47 and last traded at $23.0860. 225,451 shares traded hands during trading, a decline of 39% from the average session volume of 371,328 shares. The stock had previously closed at $20.99.

Wall Street Analysts Forecast Growth

Several research firms have recently weighed in on DBVT. Guggenheim reissued a “buy” rating and issued a $51.00 target price (up from $35.00) on shares of DBV Technologies in a research report on Wednesday, December 17th. Citigroup reiterated an “outperform” rating on shares of DBV Technologies in a research note on Wednesday, December 17th. Citizens Jmp boosted their price objective on DBV Technologies from $21.00 to $45.00 and gave the company a “market outperform” rating in a report on Wednesday, December 17th. Wall Street Zen upgraded DBV Technologies from a “sell” rating to a “hold” rating in a research note on Sunday, February 8th. Finally, Cantor Fitzgerald set a $48.00 target price on DBV Technologies in a report on Wednesday, December 17th. Two investment analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, one has given a Hold rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat, DBV Technologies presently has an average rating of “Moderate Buy” and an average price target of $38.25.

DBV Technologies Trading Up 4.2%

The firm has a market capitalization of $1.25 billion, a price-to-earnings ratio of -4.41 and a beta of -0.97. The business has a 50-day moving average price of $20.74 and a two-hundred day moving average price of $15.91.

Insider Transactions at DBV Technologies

In other DBV Technologies news, major shareholder Bpifrance Epic sold 1,292,103 shares of the firm’s stock in a transaction on Thursday, December 18th. The stock was sold at an average price of $4.19, for a total value of $5,413,911.57. Following the sale, the insider directly owned 7,303,369 shares in the company, valued at approximately $30,601,116.11. This trade represents a 15.03% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Insiders sold 3,369,627 shares of company stock valued at $15,489,908 in the last quarter. Company insiders own 1.44% of the company’s stock.

Institutional Trading of DBV Technologies

A number of large investors have recently modified their holdings of DBVT. Allworth Financial LP acquired a new position in DBV Technologies during the 4th quarter valued at about $32,000. Royal Bank of Canada bought a new stake in shares of DBV Technologies during the fourth quarter valued at approximately $34,000. New York State Common Retirement Fund acquired a new position in shares of DBV Technologies during the third quarter worth approximately $34,000. GAMMA Investing LLC boosted its position in shares of DBV Technologies by 38.4% during the fourth quarter. GAMMA Investing LLC now owns 2,680 shares of the company’s stock worth $51,000 after buying an additional 744 shares during the period. Finally, Truvestments Capital LLC grew its holdings in DBV Technologies by 71.3% in the 4th quarter. Truvestments Capital LLC now owns 3,892 shares of the company’s stock worth $75,000 after buying an additional 1,620 shares in the last quarter. Institutional investors and hedge funds own 71.74% of the company’s stock.

DBV Technologies Company Profile

DBV Technologies SA is a clinical-stage biopharmaceutical company engaged in developing immunotherapies for allergic diseases. The company specializes in epicutaneous immunotherapy, leveraging its proprietary Viaskin platform to deliver biologically active compounds across intact skin without needles or injections. Through this approach, DBV aims to modulate patients’ immune response to specific allergens, offering a potentially safer and more convenient alternative to traditional therapies.

The company’s lead product candidate, Viaskin Peanut, is designed for the treatment of peanut allergy in children and adolescents.